Spex Capital, a London-based early-stage investor backing innovative healthtech solutions, has announced today the launch of a new €100 million global healthtech fund. The fund’s mission is to help solve the world’s healthcare problems.
From seed to Series A, Spex Venture HealthTech Fund will invest up to €5 million in early-stage healthtech startups worldwide. Already, Spex Capital has closed 10 investments in the healthtech space. With the new fund, it aims to invest in the next generation of healthcare innovators.
Partnership with MedCity
The firm was founded in 2021 by serial healthtech entrepreneur Claudio D’Angelo and has a partnership with MedCity, a life sciences cluster in London that has close ties to the NHS. A joint investment programme of the partnership contributes to the growth of around 1,000 healthcare companies each year.
Claudio D’Angelo, Founder and CEO of Spex Capital, said: “Even before Covid-19, the drive for countries to make better use of digital technology in healthcare had already begun. With this fund, our partnership with MedCity, and a broad network of high calibre Senior Advisors, we will have unparalleled access to invest in the best startups within this space.”
As part of the partnership, Spex Capital has also appointed Brent Stackhouse, the Managing Director of Mount Sinai Ventures, who has extensive US healthcare experience.
Brent Stackhouse, Senior Partner, Mount Sinai Ventures, said: “I’m excited to take part in the launch of the Spex Venture HealthTech Fund at a time of radical change for the healthtech sector.”